QQQ   444.84 (-0.17%)
AAPL   173.99 (-3.16%)
MSFT   415.48 (+0.00%)
META   502.00 (-0.06%)
GOOGL   132.58 (-3.33%)
AMZN   178.13 (-0.05%)
TSLA   187.45 (-7.50%)
NVDA   866.97 (+5.37%)
NIO   5.37 (-7.09%)
AMD   207.63 (+2.46%)
BABA   71.87 (-3.69%)
T   16.83 (-0.88%)
F   12.88 (+3.45%)
MU   96.69 (+1.62%)
CGC   3.01 (-6.23%)
GE   160.35 (+1.07%)
DIS   113.53 (+1.41%)
AMC   4.30 (-1.38%)
PFE   25.91 (-2.56%)
PYPL   59.73 (-1.34%)
XOM   104.30 (-1.46%)
QQQ   444.84 (-0.17%)
AAPL   173.99 (-3.16%)
MSFT   415.48 (+0.00%)
META   502.00 (-0.06%)
GOOGL   132.58 (-3.33%)
AMZN   178.13 (-0.05%)
TSLA   187.45 (-7.50%)
NVDA   866.97 (+5.37%)
NIO   5.37 (-7.09%)
AMD   207.63 (+2.46%)
BABA   71.87 (-3.69%)
T   16.83 (-0.88%)
F   12.88 (+3.45%)
MU   96.69 (+1.62%)
CGC   3.01 (-6.23%)
GE   160.35 (+1.07%)
DIS   113.53 (+1.41%)
AMC   4.30 (-1.38%)
PFE   25.91 (-2.56%)
PYPL   59.73 (-1.34%)
XOM   104.30 (-1.46%)
QQQ   444.84 (-0.17%)
AAPL   173.99 (-3.16%)
MSFT   415.48 (+0.00%)
META   502.00 (-0.06%)
GOOGL   132.58 (-3.33%)
AMZN   178.13 (-0.05%)
TSLA   187.45 (-7.50%)
NVDA   866.97 (+5.37%)
NIO   5.37 (-7.09%)
AMD   207.63 (+2.46%)
BABA   71.87 (-3.69%)
T   16.83 (-0.88%)
F   12.88 (+3.45%)
MU   96.69 (+1.62%)
CGC   3.01 (-6.23%)
GE   160.35 (+1.07%)
DIS   113.53 (+1.41%)
AMC   4.30 (-1.38%)
PFE   25.91 (-2.56%)
PYPL   59.73 (-1.34%)
XOM   104.30 (-1.46%)
QQQ   444.84 (-0.17%)
AAPL   173.99 (-3.16%)
MSFT   415.48 (+0.00%)
META   502.00 (-0.06%)
GOOGL   132.58 (-3.33%)
AMZN   178.13 (-0.05%)
TSLA   187.45 (-7.50%)
NVDA   866.97 (+5.37%)
NIO   5.37 (-7.09%)
AMD   207.63 (+2.46%)
BABA   71.87 (-3.69%)
T   16.83 (-0.88%)
F   12.88 (+3.45%)
MU   96.69 (+1.62%)
CGC   3.01 (-6.23%)
GE   160.35 (+1.07%)
DIS   113.53 (+1.41%)
AMC   4.30 (-1.38%)
PFE   25.91 (-2.56%)
PYPL   59.73 (-1.34%)
XOM   104.30 (-1.46%)
NASDAQ:IVA

Inventiva (IVA) Stock Price, News & Analysis

$3.82
-0.22 (-5.45%)
(As of 12:44 PM ET)
Today's Range
$3.70
$3.82
50-Day Range
$3.27
$4.66
52-Week Range
$2.22
$5.44
Volume
57,657 shs
Average Volume
22,641 shs
Market Capitalization
$199.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

Inventiva MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
330.1% Upside
$16.00 Price Target
Short Interest
Healthy
0.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.41mentions of Inventiva in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.39) to ($2.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.62 out of 5 stars

Medical Sector

514th out of 948 stocks

Pharmaceutical Preparations Industry

241st out of 441 stocks


IVA stock logo

About Inventiva Stock (NASDAQ:IVA)

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Stock Price History

IVA Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Inventiva SA ADR IVA
Analysts’ Top Healthcare Picks: Morphosys Ag (MOR), Abbott Labs (ABT)
Inventiva reports 9M results
Inventiva Share Price (IVA.PA)
See More Headlines
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/04/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IVA
Fax
N/A
Employees
117
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$25.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+330.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.01 million
Book Value
$1.14 per share

Miscellaneous

Free Float
35,439,000
Market Cap
$193.87 million
Optionable
Not Optionable
Beta
0.91

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Frederic Cren (Age 58)
    Co-Founder, CEO & Chairman
    Comp: $545.79k
  • Dr. Pierre Broqua Ph.D. (Age 62)
    Co-Founder, Chief Scientific Officer, Deputy CEO & Director
    Comp: $409.38k
  • Mr. Jean Volatier (Age 59)
    Chief Financial Officer
  • Alice Roudot-Ketelers Pharm.D.
    Chief Operating Officer
  • Mr. Eric Duranson L.L.M. (Age 50)
    General Counsel
  • Ms. Nathalie Harroy (Age 57)
    Head of Human Resources
  • Dr. Michael Cooreman (Age 66)
    Chief Medical Officer














IVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IVA shares.
View IVA analyst ratings
or view top-rated stocks.

What is Inventiva's stock price target for 2024?

8 analysts have issued twelve-month price targets for Inventiva's stock. Their IVA share price targets range from $11.00 to $25.00. On average, they expect the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 330.1% from the stock's current price.
View analysts price targets for IVA
or view top-rated stocks among Wall Street analysts.

How have IVA shares performed in 2024?

Inventiva's stock was trading at $4.52 at the start of the year. Since then, IVA shares have decreased by 17.7% and is now trading at $3.72.
View the best growth stocks for 2024 here
.

When is Inventiva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our IVA earnings forecast
.

When did Inventiva IPO?

(IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IVA) was last updated on 3/4/2024 by MarketBeat.com Staff